Results 81 to 90 of about 7,483 (199)

T helper cell subsets specific for Pseudomonas aeruginosa in healthy individuals and patients with cystic fibrosis.

open access: yesPLoS ONE, 2014
BackgroundWe set out to determine the magnitude of antigen-specific memory T helper cell responses to Pseudomonas aeruginosa in healthy humans and patients with cystic fibrosis.MethodsPeripheral blood human memory CD4(+) T cells were co-cultured with ...
Hannah K Bayes   +3 more
doaj   +1 more source

Swiss Practice Recommendations for Chronic Prurigo Including Prurigo Nodularis

open access: yesInternational Journal of Dermatology, EarlyView.
Chronic prurigo, including prurigo nodularis, is a chronic, often treatment‐refractory condition characterized by persistent pruritus and chronic scratch lesions. Advances in the understanding of its underlying pathophysiology have enabled the development of novel targeted therapies; however, management remains challenging due to the expanding range of
Simon M. Mueller   +11 more
wiley   +1 more source

Correlation between the percentages of Th22 cells and the percentages of Th17 cells in AS and RA patients. [PDF]

open access: yes, 2012
a, Positive correlation was found between Th22 cells and Th17 cells in AS patients. b, Positive correlation was found between Th22 cells and Th17 cells in RA patients.
Lei Qi (173882)   +11 more
core   +1 more source

Mapping malignant T‐cell states and immune circuits in Sézary syndrome by single‐cell analysis

open access: yesJournal of the European Academy of Dermatology and Venereology, EarlyView.
Peripheral blood single‐cell RNA‐seq from leukaemic CTCL defined three malignant T‐cell programmes: MTC CM, MTC Reg and MTC E/EM, each with distinct features and candidate vulnerabilities. For example, inferred immune circuits highlighted actionable IL‐10/JAK–TYK2–STAT3 signalling, KIR–MHC I inhibitory interactions and myeloid/B‐cell inflammatory and ...
Beth A. Childs   +6 more
wiley   +1 more source

Elevated Th22 cells and related cytokines in patients with epithelial ovarian cancer

open access: yesMedicine, 2017
This study is conducted to investigate the involvement of T-helper (Th) cells and regulatory T cells in epithelial ovarian cancer (EOC).The percentages of Th22, Th17, Th1, and regulatory T cells in the peripheral blood of EOC patients, benign ovarian epithelial neoplasm (BOEN) patients, and healthy control (HC) were examined by flow cytometry.
Wang, Ting   +8 more
openaire   +2 more sources

Identifizierung und Charakterisierung neuer regulierender Faktoren von Th17 und Th22-Zellen [PDF]

open access: yes, 2018
This study identified an upregulated expression of LINGO4 in Th17 cells and FOXO4 in IL-22 producing as well as Th22 cells. LINGO4 expression strongly correlated with the expression of the key transcription factor of Th17 cells, RORC2, and was identified
Atenhan, Anne
core  

A novel, dual cytokine-secretion assay for the purification of human Th22 cells that do not co-produce IL-17A [PDF]

open access: yes, 2015
BACKGROUND Interleukin-22 is produced by certain T helper cells subsets (Th17, Th22) and at lower levels by γ-δ T cells, NKT and innate lymphoid cells. Th22 cells are unique immune cells that regulate tissue responses by IL-22 production.
C. A. Akdis   +13 more
core   +1 more source

Role of Th22 cells in Helicobacter pylori-related gastritis and peptic ulcer diseases [PDF]

open access: yes, 2019
Helicobacter pylori (H. pylori) has been shown to be one of the leading causes of peptic ulcer diseases (PUDs) and gastritis. T helper-22 (Th22) cells and its most important cytokine, interleukin-22 (IL-22) are importantly active in inflammation and ...
Shafigh, Mohammadhadi   +7 more
core  

OX40/OX40L modulation: A target for regulating T cells in cutaneous inflammatory disorders

open access: yesJournal of the European Academy of Dermatology and Venereology, EarlyView.
OX40 and OX40L are a co‐stimulatory immune checkpoint pair. Modulation of this pair impacts multiple immune phenotypes and is an attractive target for immunotherapy in dermatological disorders. Trials are underway with the majority in atopic dermatitis and currently in phase 3 trials.
Aditya K. Gupta   +4 more
wiley   +1 more source

Home - About - Disclaimer - Privacy